Investors turn on biotechnology as largest ETF in sector suffers record withdrawals

But analysts divided over longer-term prospects: Some see end of bull market while others see pause

Apr 8, 2014 @ 1:19 pm

Investors pulled a record $372 million from the biggest biotechnology exchange-traded fund in its worst day of redemptions ever.

The withdrawals from the iShares Nasdaq Biotechnology ETF on April 4 were the most since its 2001 inception, with 7.5% of the fund's $4.98 billion in total assets leaving what is the biggest biotech-focused ETF, according to data compiled by Bloomberg. It follows a lengthy run-up in biotechnology industry stocks.

Now, “that momentum money is being sucked out,” said Geoffrey Porges, an analyst with Sanford C. Bernstein & Co.

Health-care ETFs have boomed this year, attracting more deposits than any other sector and adding $3.98 billion since Jan. 1. That increase has been spurred by a biotechnology sector that last year gained 74%, compared with a 30% increase in the S&P 500.

Recently, investors have begun to question whether biotechnology stocks are in a bubble and whether the companies developing complex and often expensive medicines are worth their high valuations. After gaining 11% in January and February, the Standard & Poor's 500 Biotechnology Index has fallen 11% since March 3.


“We consider the sector's run-up, which has been remarkable, to be getting into its very final innings,” Mr. Porges said. Stocks could be set for a significant move downward, especially if generalist investors decide to leave, he said.

Robyn Karnauskas, an analyst with Deutsche Bank AG, disagrees.

“The way I see it, I think we've turned the corner,” she said. “I don't see this as downside. When the fundamentals are strong and you have catalysts like earnings, I don't think we're headed for a bear period.”

The Nasdaq Biotechnology exchange-traded fund, also known as the IBB, is made up of the shares for 122 biotechnology and medical companies including its biggest holdings — Amgen Inc., Gilead Sciences Inc. and Celgene Corp. The SPDR S&P Biotech ETF also had its worst day since May 2010 on April 4 as investors pulled $80 million, or 6.6% of assets.


There are other signs investors are pessimistic. In the Nasdaq Biotechnology ETF, 15% of all the shares outstanding — $665 million worth — are short, meaning investors have bet they'll fall in value, according to data compiled by Bloomberg and Markit Group Ltd.

Other health-care focused ETFs with more diversified assets didn't see similar withdrawals. For example, the Health Care Select Sector SPDR Fund, which also has pharmaceuticals and health-care products and services stocks, gained $90 million on the biotech ETF's worst day.

Some of that may be profit-taking near the end of the quarter, said Paul Weisbruch, a vice president at Street One Financial. “It's a reflection of, probably, end-of-the-quarter selling of the winners if you will, because biotechs have done really well,” he said. His firm analyzes and trades ETFs.

Investors aren't just moving out of biotech funds, they're also exiting more volatile sectors that haven't fared well recently, he said.

Industries with high volatility are what “you see selling off — small caps, social media,” Mr. Weisbruch said. “As fast as it went up, it's coming down.”

(Bloomberg News)


What do you think?

View comments

Recommended for you

Sponsored financial news

Featured video


Diversity & Inclusion Awards: 2018 nominations are open

Editor Fred Gabriel and special projects editor Liz Skinner discuss the nomination process for InvestmentNews' inaugural Diversity & Inclusion awards.

Latest news & opinion

Cetera reportedly exploring $1.5 billion sale

The company confirmed it's talking to investment bankers to 'explore how to best optimize [its] capital structure at lower costs.'

SEC Chairman Jay Clayton outlines goals for a new fiduciary standard

Rule should provide clarity on role of adviser, enhanced investor protection and regulatory coordination.

Advisers bemoan LPL's technology platform change

Those in a private LinkedIn chat room were sounding off about fears the independent broker-dealer will require a move to ClientWorks before it is fully ready.

Speculation mounts on whether others will follow UBS' latest move to prevent brokers from leaving

UBS brokers must sign a 12-month non-solicit agreement if they want their 2017 bonuses.

Maryland jumps into fiduciary fray with legislation requiring brokers to act in best interests of clients

Legislation requires brokers to act in the best interests of clients.


Hi! Glad you're here and we hope you like all the great work we do here at InvestmentNews. But what we do is expensive and is funded in part by our sponsors. So won't you show our sponsors a little love by whitelisting It'll help us continue to serve you.

Yes, show me how to whitelist

Ad blocker detected. Please whitelist us or give premium a try.


Subscribe and Save 60%

Premium Access
Print + Digital

Learn more
Subscribe to Print